AGY logo

Allergy Therapeutics plc Stock Price

AIM:AGY Community·UK£712.4m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

AGY Share Price Performance

UK£0.12
0.04 (61.11%)
UK£0.12
0.04 (61.11%)
Price UK£0.12

AGY Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Medium-low risk with weak fundamentals.

6 Risks
0 Rewards

Allergy Therapeutics plc Key Details

UK£55.0m

Revenue

UK£25.7m

Cost of Revenue

UK£29.3m

Gross Profit

UK£69.4m

Other Expenses

-UK£40.1m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-0.0065
53.23%
-72.91%
-189.6%
View Full Analysis

About AGY

Founded
1998
Employees
584
CEO
Manuel Llobet
WebsiteView website
www.allergytherapeutics.com

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.

Recent AGY News & Updates

Recent updates

No updates